Pioneering Spine Surgeon to Present Landmark Synergy Disc Trial Results

Dr. Todd Lanman to unveil first full data from FDA-approved motion-preserving cervical disc at ISASS 2026 conference

Apr. 3, 2026 at 3:37pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image of the human cervical spine, with the vertebrae and discs glowing in shades of blue and green against a dark background, conveying the fluid, dynamic motion-preserving capabilities of the Synergy Disc technology.Pioneering spinal technology aims to preserve natural cervical motion and alignment.Beverly Hills Today

Following the recent FDA approval of the Synergy Disc, pioneering spine surgeon Dr. Todd H. Lanman will present the full results from the U.S. Investigational Device Exemption (IDE) clinical trial at the International Society for the Advancement of Spine Surgery (ISASS) 2026 Annual Conference in Miami Beach. Dr. Lanman served as a principal investigator in the multicenter study evaluating the motion-preserving cervical artificial disc, which demonstrated superiority to traditional fusion surgery on the primary endpoint of composite clinical success at 24 months.

Why it matters

The Synergy Disc represents a significant advancement in cervical spine technology, offering patients meaningful reductions in pain, improved function, and higher satisfaction compared to fusion surgery. Dr. Lanman's presentation of the landmark IDE trial data will provide spine surgeons with critical insights into the future of motion-preserving spinal procedures.

The details

In the IDE trial, the Synergy Disc achieved an 87.1% composite clinical success rate, significantly higher than the 75.2% rate in the fusion control group. Additional key findings included 91.7% of patients achieving clinically meaningful improvement on the Neck Disability Index, lower mean neck and arm pain scores, improved segmental alignment, and higher patient satisfaction compared to fusion.

  • The Synergy Disc received FDA approval in early 2026.
  • Dr. Lanman will present the full IDE trial results at the ISASS 2026 Annual Conference in Miami Beach from April 9-11.

The players

Todd H. Lanman, MD

A pioneering spinal neurosurgeon with over three decades of experience, Dr. Lanman served as a principal investigator in the multicenter U.S. IDE study evaluating the Synergy Disc motion-preserving cervical artificial disc.

Synergy Spine Solutions

A medical device company focused on improving the quality of life for spine surgery patients, Synergy Spine Solutions developed the FDA-approved Synergy Disc featuring a built-in lordotic core designed to preserve motion and improve spinal alignment.

Got photos? Submit your photos here. ›

What they’re saying

“Artificial disc replacement continues to evolve rapidly, and these IDE results tell a clear story – meaningful reductions in neck and arm pain, better function, and higher patient satisfaction over fusion. For patients, that is just not a statistic. That is the ability to return to an active, unrestricted life. That is what motion preservation is ultimately about.”

— Todd H. Lanman, MD, Pioneering Spinal Neurosurgeon

What’s next

Dr. Lanman's presentation at ISASS 2026 will provide spine surgeons with a detailed review of the IDE trial methodology, clinical outcomes, and implications for the future of cervical motion-preserving surgery.

The takeaway

The Synergy Disc represents a significant advancement in cervical spine technology, offering patients meaningful improvements in pain, function, and satisfaction compared to traditional fusion surgery. Dr. Lanman's landmark IDE trial data will help drive the continued evolution of motion-preserving spinal procedures.